Garrett Winslow
CIK 1803773 · General Counsel · last filed 2026-07-07
Garrett Winslow is a General Counsel who has filed 14 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for DMRA, was dated Jul 7, 2026. Across all open-market trades the lifetime net is −$2.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $74.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$74.6K
3
14
-$2.6K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DMRA | General Counsel | 2,534 | $29.42 | $74.6K | -$7.3K | 2 | 2026-07-07 |
| Damora Therapeutics, Inc. (GLTO) Delisted | General Counsel | 2,109 | $28.69 | $60.5K | $5.6K | 10 | 2026-01-06 |
| F-star Therapeutics, Inc. (SBPH) Delisted | General Counsel and Secretary | 18,750 | — | — | -$833 | 2 | 2020-11-23 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-07 | DMRA | Mixed | +435 | -$7.3K | EDGAR |
| 2026-03-25 | DMRA | Grant (A) | — | $0 | EDGAR |
| 2026-01-06 | Damora Therapeutics, Inc. (GLTO) Delisted | Mixed | +425 | -$5.5K | EDGAR |
| 2025-07-08 | Damora Therapeutics, Inc. (GLTO) Delisted | Mixed | +420 | -$881 | EDGAR |
| 2025-01-07 | Damora Therapeutics, Inc. (GLTO) Delisted | Mixed | +849 | -$2.6K | EDGAR |
| 2024-10-11 | Damora Therapeutics, Inc. (GLTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-05 | Damora Therapeutics, Inc. (GLTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | Damora Therapeutics, Inc. (GLTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-01-06 | Damora Therapeutics, Inc. (GLTO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-06 | Damora Therapeutics, Inc. (GLTO) Delisted | Buy (P) | +2,000 | $5.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.